Annual Report

Overview

The report presents Marksans Pharma's FY2023-24 consolidated revenue of ₹21,774.07 million and its global pharmaceutical footprint. It describes the acquisition of a Goa manufacturing facility and the group's four manufacturing units. Sustainability disclosures quantify 82,308,912.12 MJ of total energy consumption and 28.755 metric tonnes of waste generated, alongside emissions, water, safety and CSR reporting.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2023-2024
Period: 1 April 2023 – 31 March 2024
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services